Academic Journals Database
Disseminating quality controlled scientific knowledge

High-Dose Ibuprofen in Cystic Fibrosis

Author(s): Larry C. Lands | Nurlan Dauletbaev

Journal: Pharmaceuticals
ISSN 1424-8247

Volume: 3;
Issue: 7;
Start page: 2213;
Date: 2010;
Original page

Keywords: ibuprofen | interleukin-8 | neutrophils | cystic fibrosis | CFTR

Cystic Fibrosis (CF) is the most common lethal genetic disorder in North America and Europe. Most patients succumb to progressive lung disease characterized by an exaggerated neutrophilic inflammation. In animal models of chronic infection, high-dose ibuprofen was demonstrated to reduce inflammation without hindering bacterial clearance. This led to two clinical trials, which demonstrated a benefit in slowing the progression of lung disease in CF. However, concerns about potential adverse effects have limited the use of high-dose ibuprofen in CF patients. There are a variety of potential mechanisms to account for the observed clinical benefit. A better understanding of these mechanisms could potentially lead to more targeted and better-tolerated anti-inflammatory therapies.
Why do you need a reservation system?      Affiliate Program